Takeda provide regulatory and clinical update for Feraheme Injection AMAG Pharmaceuticals.

Both trials will evaluate changes in hemoglobin levels as well as other efficacy and security endpoints. The program is now enrolling patients; the ongoing companies expect that it will require up to 1. 5 years to complete enrollment. Related StoriesEKF highlighting warmth and humidity compatible POC hemoglobin analyzer at Arab Wellness 2015Point of treatment measurement of hemoglobin: an interview with Katja Lemburg, EKF DiagnosticsDeaths from avoidable risk elements: an interview with Dr Ali Mokdad, IHME We’ve thus far made great progress on our key objectives for this 12 months, stated Brian J.G. Pereira, MD, Chief and President Executive Officer of AMAG Pharmaceuticals, Inc. With the MAA submitting validated by the EMA and the global registrational plan for Feraheme for the broader indication of the treatment of iron deficiency anemia underway, we are many steps closer to expanding the reach of Feraheme, both also to new individual populations geographically.‘This achievement is normally a testament to the medical community that the ACR is usually focused on providing radiologists with useful CME opportunities that promote transformation and quality improvement. ACR staff and the ACR Commission on Education have done exemplary work. We are pleased with this achievement extremely,’ stated Cheri L. Canon, M.D., FACR, chair of the ACR Commission on Education.. Aging Japanese population driving high CAP burden By Joanna Lyford, Senior medwireNews Reporter There exists a high incidence of community-acquired pneumonia in Kochi Town in western Japan, which is explained by the huge proportion of elderly inhabitants primarily, researchers statement.

You Might Also Like